Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024)

Zevra Therapeutics (ZVRA) posted Finished Goods of $1.1 million for Q3 2024, down 45.35% on a QoQ basis from $2.1 million in Q2 2024.

Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024) Analysis & Trends

Zevra Therapeutics' Finished Goods history runs 2 years deep, the most recent figure standing at $1.1 million for Q3 2024.

Quarterly Finished Goods changed N/A year-over-year to $1.1 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.1 million (changed N/A YoY) and the FY2023 annual result came in at $5.0 million, changed N/A from the prior year.
Finished Goods was $1.1 million for Q3 2024 at Zevra Therapeutics, down from $2.1 million in the prior quarter.
Across five years, Finished Goods topped out at $5.1 million in Q1 2024 and bottomed at $1.1 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Zevra Therapeutics	239.71 Mn	39.10 Mn	34.32 Mn

Download Data